Thyroid cancer

Ipsen Opts-in to Join Exelixis With Ongoing Development of Cabometyx® for People Living With a Form of Thyroid Cancer, Based on Promising Interim Results

Tuesday, May 11, 2021 - 10:00pm

Cabometyx is marketed by Exelixis in the U.S. and by Takeda Pharmaceutical Company Limited in Japan.

Key Points: 
  • Cabometyx is marketed by Exelixis in the U.S. and by Takeda Pharmaceutical Company Limited in Japan.
  • Cabometyx is a registered trademark of Exelixis.\nIpsen is a global mid-size biopharmaceutical company with a focus on transformative medicines in Oncology, Rare Disease and Neuroscience.
  • For more information on Ipsen, visit www.ipsen.com\nThe forward-looking statements, objectives and targets contained herein are based on the Group\xe2\x80\x99s management strategy, current views and assumptions.
  • Oncol Lett 19: 1985-1992, 2020. doi: 10.3892/ol.2020.11304.\nWorden F. Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer.

MEDO receives FDA approval to Revolutionize Thyroid Ultrasound.

Thursday, May 6, 2021 - 6:24pm

This high volume is due to the fact that lumps, or "nodules" on the thyroid gland are common and although usually benign, can be cancerous.

Key Points: 
  • This high volume is due to the fact that lumps, or "nodules" on the thyroid gland are common and although usually benign, can be cancerous.
  • Using artificial intelligence, Medo has revolutionized the process of performing thyroid studies and turned it into a seamless, fast,and objective workflow.\nWith Medo-Thyroid, the user simply obtains quick video \'sweeps\' of each side of the thyroid gland.
  • Jacob Jaremko, a radiologist and co-founder of Medo, explains that "Medo-Thyroid makes thyroid ultrasound a less frustrating test, by presenting thyroid measurements and nodule characteristics in a convenient format.
  • Dornoosh Zonoobi, co-founder and CEO of Medo, notes that: "With this product, Medo provides both clinical and financial value to the stakeholders.

Veracyte Announces New Data Relating to Prosigna Breast Cancer Test to Be Presented at ESMO Breast Cancer Virtual Congress

Tuesday, May 4, 2021 - 9:45pm

The company\xe2\x80\x99s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping and renal cancer tests are in development.

Key Points: 
  • The company\xe2\x80\x99s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping and renal cancer tests are in development.
  • With Veracyte\xe2\x80\x99s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide.
  • A copy of these documents can be found at the Investors section of our website at www.veracyte.com .
  • The risks and uncertainties may be amplified by the COVID-19 pandemic, which has caused significant economic uncertainty.

Irini E. Veronikis, MD, FACP, FACE is recognized by Continental Who's Who

Tuesday, April 27, 2021 - 7:19pm

Today, the Hospital continues to provide compassionate medical and specialty care on their centrally located campus at I-270 and I-64/US 40.

Key Points: 
  • Today, the Hospital continues to provide compassionate medical and specialty care on their centrally located campus at I-270 and I-64/US 40.
  • She is currently serving patients in private practice and affiliated with Mercy Hospital St. Louis in Missouri.
  • Licensed to practice medicine in Missouri and Pennsylvania, her practice focuses on thyroid disorders and cancer of the thyroid.
  • She also dedicates this in the loving memory of her mentor Louis Braverman, MD.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/irini-e-veronikis-md-facp-face-i...\n"

New Thyroid Tracker App, ThyForLife: Launched on Google Play Store

Wednesday, April 21, 2021 - 8:54pm

b'ThyForLife , a free thyroid tracking app, has launched its first official product following a successful beta app launch in May 2020 where more than 8,000 thyroid patients around the world chose the tool to better understand and manage their thyroid conditions.

Key Points: 
  • b'ThyForLife , a free thyroid tracking app, has launched its first official product following a successful beta app launch in May 2020 where more than 8,000 thyroid patients around the world chose the tool to better understand and manage their thyroid conditions.
  • Downloadable on all mobile Android devices globally, ThyForLife allows users to organize and store all of thyroid patient medical data including bloodwork, medication, weight, and symptoms.\nThyroid cancer survivor, Founder and CEO of ThyForLife, Natalia Lumen, created the mobile app as a way to give back to her community.
  • With a growing team of 12, Lumen commented, \xe2\x80\x9cWe\xe2\x80\x99re committed to improving the lives of thyroid patients by providing accessible information and thyroid health support in your pocket.\xe2\x80\x9d\nThe latest version of the app converts lab results onto a single scale.
  • Among the variety of different reference ranges and units across lab results, having them on one scale and graph creates a more organized and manageable system for patients.

Veracyte to Release First Quarter 2021 Financial Results on May 10, 2021

Tuesday, April 20, 2021 - 6:00pm

The company\xe2\x80\x99s growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment.

Key Points: 
  • The company\xe2\x80\x99s growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment.
  • The company\xe2\x80\x99s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping and renal cancer tests are in development.
  • With Veracyte\xe2\x80\x99s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide.
  • For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210420005972/en/\n'

Veracyte Commends New USPSTF Lung Cancer Screening Guidelines

Wednesday, March 10, 2021 - 10:15pm

(Nasdaq: VCYT) today commended the U.S. Preventive Services Task Force (USPSTF) for its new, revised recommendations that expand eligibility for lung cancer screening.

Key Points: 
  • (Nasdaq: VCYT) today commended the U.S. Preventive Services Task Force (USPSTF) for its new, revised recommendations that expand eligibility for lung cancer screening.
  • We commend the USPSTF for their new lung cancer screening recommendations, which will help ensure that more lives are saved through early detection, said Bonnie Anderson, Veracytes chairman and chief executive officer.
  • Much work remains in the fight against lung cancer, including ensuring that physicians have optimal tools to help guide patient care when potentially cancerous lung nodules are found through screening.
  • The companys tests in lung cancer, breast cancer, thyroid cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping test is in development.

Interpace Biosciences Announces Contract for Thyroid Testing with Blue Cross Blue Shield of Illinois

Thursday, February 25, 2021 - 9:30pm

Tom Burnell, President and CEO of Interpace Biosciences, stated, We are pleased that Blue Cross Blue Shield of Illinois, a division of one of the largest payers in United States, Health Care Services Corporation, has agreed to contract with us for our molecular tests, making them available to their members on an in-network basis.

Key Points: 
  • Tom Burnell, President and CEO of Interpace Biosciences, stated, We are pleased that Blue Cross Blue Shield of Illinois, a division of one of the largest payers in United States, Health Care Services Corporation, has agreed to contract with us for our molecular tests, making them available to their members on an in-network basis.
  • ThyGeNEXT utilizes state-of-the-art next-generation sequencing (NGS) to identify more than 100 genetic alterations associated with papillary and follicular thyroid carcinomas, the two most common forms of thyroid cancer, as well as Medullary Thyroid Carcinoma.
  • ThyGeNEXT and ThyraMIR reflex testing yields high predictive value in determining the presence and absence of cancer in thyroid nodules.
  • Pharma services, through Interpace Pharma Solutions, provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries.

Exelixis Announces Breakthrough Therapy Designation Granted to Cabozantinib for the Treatment of Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Thursday, February 25, 2021 - 1:00pm

In 2016, Exelixis granted Ipsen exclusive rights for the commercialization and further clinical development of cabozantinib outside of the United States and Japan.

Key Points: 
  • In 2016, Exelixis granted Ipsen exclusive rights for the commercialization and further clinical development of cabozantinib outside of the United States and Japan.
  • The incidence of Grade 3 to 5 hemorrhagic events was 5% in CABOMETYX patients in RCC and HCC studies.
  • Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer.
  • Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.

Veracyte to Release Fourth Quarter and Full-Year 2020 Financial Results on February 17, 2021

Wednesday, February 10, 2021 - 1:15pm

The companys tests in thyroid cancer, lung cancer, breast cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping test is in development.

Key Points: 
  • The companys tests in thyroid cancer, lung cancer, breast cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping test is in development.
  • With Veracytes exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide.
  • For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).
  • Veracyte, Afirma, Percepta, Envisia, Prosigna, "Know by Design" and the Veracyte, Afirma, Percepta, Envisia and Prosigna logos are registered trademarks of Veracyte in the U.S. and selected countries.